Overview

Our
Company

NorthStar is a radiopharmaceutical company, developing novel ways to help detect and cure cancer and other serious diseases. We are the first and only U.S. company housing commercial scale radioisotope production and radiopharmaceutical CDMO services co-located on the same campus.

 

We are routinely producing Copper-67 (Cu-67), used in clinical trials for the treatment of several types of cancer.

IN OUR EFFORTS TO DELIVER
CREATIVE SOLUTIONS, WE
CLEARLY DEFINE

WHO
WE ARE

We are innovators who revolutionized the U.S. production of Mo-99, and now Cu-67. Actinium-225 (Ac-225) will begin production soon. We are dedicated to preserving the environment using non-uranium production methods. We are pioneers working with industry leaders to develop and commercialize new diagnostics and radiopharmaceutical therapies that will serve the next generation of medical advances for patients.

The next major horizon includes a world class Radiopharmaceutical CDMO/CMO, launching production operations in early 2025.

THE RAPIDLY EVOLVING
RADIOPHARMACEUTICAL MARKET
DEMANDS INNOVATIVE THINKING,
LIKE THAT PIONEERED BY OUR

LEADERSHIP
TEAM

Our executive team brings proven experience and expertise in developing and commercializing innovative nuclear medicine products and technologies.

LATEST NEWS, PRESS RELEASES & EVENTS


Press Releases - Apr 15, 2024
NorthStar Appoints Peter Pfreundschuh to Board of Managers

Press Releases - Apr 10, 2024
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials

Press Releases - Apr 4, 2024
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit
Jul 30, 2024 - Aug 1, 2024
Conference
3rd Annual Targeted Radiopharmaceuticals Summit US
Sponsoring, Attending